Education
About Us
Working with TipRanks
Follow Us
JD Health International, Inc. (HK:6618)
:6618
RESEARCH TOOLSreports
Earnings Data
Report Date
Aug 26, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.88Last Year’s EPS
0.7Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 06, 2025
|% Change Since: -14.23%
|Next Earnings Date:Aug 26, 2025
Earnings Call Sentiment|Positive
JD Health demonstrated strong performance in 2024 with significant revenue growth and expansion in AI and B2C leadership. Despite some increases in expenses and slower direct sales growth, the company's strategic initiatives and robust service revenue highlight a positive outlook.Company Guidance
During the JD Health International 2024 Annual Results Conference Call, the company reported a full-year revenue of RMB58.16 billion, marking an 8.6% year-over-year increase. Excluding the pandemic-related high comparison base from the first quarter, revenue growth in the second to fourth quarters was 13.4% year-over-year. The annual active user count exceeded 183 million, with over 498,000 average daily online consultations. JD Health's direct sales revenue was RMB48.8 billion, a 6.9% increase from the previous year, driven by strong performance in pharmaceuticals. Service revenue for 2024 reached RMB9.36 billion, growing 18.9% year-over-year and comprising 16.1% of total revenue. The company's gross profit margin improved by 17 basis points to 22.9%, and non-IFRS net profit rose by 15.9% to RMB4.8 billion, achieving a margin of 8.2%. JD Health continued to enhance its omnichannel and AI initiatives, maintaining a robust cash position with RMB59.42 billion in reserves by year-end.Robust Revenue Growth
JD Health achieved a full year revenue of RMB58.16 billion in 2024, up 8.6% year-over-year, with significant growth in pharmaceutical sales and non-pharmaceutical segments.
Expansion of B2C Leadership
The company solidified its B2C leadership by increasing its omnichannel initiatives and leadership in pharmaceuticals, with a focus on imported drugs and innovative treatments.
AI Innovations
JD Health launched Jingyi Qianxun, a large language model, and other AI-powered tools to enhance doctor productivity and user experience, aiming for AI-powered transformation in healthcare.
Increased Service Revenue
Service revenue surpassed RMB9.36 billion for the year, marking an 18.9% increase year-over-year, with significant contributions from platform commissions and advertising revenue.
High-Quality Active User Base
The annual active user count exceeded 183 million, with an average daily online consultation volume of over 498,000, demonstrating strong user engagement.
---
HK:6618 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
HK:6618 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 06, 2025 | HK$38.65 | HK$40.80 | +5.56% |
| Aug 15, 2024 | HK$20.45 | HK$19.82 | -3.08% |
| Mar 20, 2024 | HK$32.15 | HK$32.05 | -0.31% |
| Aug 16, 2023 | HK$50.20 | HK$50.55 | +0.70% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does JD Health International, Inc. (HK:6618) report earnings?
JD Health International, Inc. (HK:6618) is schdueled to report earning on Aug 26, 2025, TBA Not Confirmed.
What is JD Health International, Inc. (HK:6618) earnings time?
JD Health International, Inc. (HK:6618) earnings time is at Aug 26, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of JD Health International, Inc. stock?
The P/E ratio of JD Health International, Inc. is N/A.
What is HK:6618 EPS forecast?
HK:6618 EPS forecast for the fiscal quarter 2025 (Q2) is 0.88.
---